Grace TherapeuticsGRCE +1.06%31 Days Inventory is 0.00 as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 640 Biotechnology companies, Grace Therapeutics ranks worse than 156249.84% on this metric.
The historical rank and industry rank for Grace Therapeutics's Days Inventory or its related term are showing as below:
During the past 13 years, Grace Therapeutics's highest Days Inventory was 798.44. The lowest was 798.44. And the median was 798.44.
GRCE's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 184.145 * Ranked among companies with meaningful Days Inventory only.
Grace Therapeutics's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Grace Therapeutics (NAS:GRCE) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Grace Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Grace Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Grace Therapeutics Days Inventory Related Terms
Grace Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Grace Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRCE vs PSTV, ATNM, NNVC: Days Inventory Comparison
For the Biotechnology subindustry, Grace Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grace Therapeutics (GRCE) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Grace Therapeutics and its competitors. Over the past decade, Grace Therapeutics' Days Inventory has ranged from 798.44 to 798.44. According to the industry distribution chart, Grace Therapeutics ranks #999999 out of 640 companies in the Biotechnology industry.
Is Grace Therapeutics' Days Inventory too high?
Grace Therapeutics' current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 798.44 to a high of 798.44. Based on the distribution chart, Grace Therapeutics ranks #999999 out of 640 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Days Inventory compare to PSTV and ATNM?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #999999 out of 640 companies for Days Inventory. This places Grace Therapeutics in the lower half of its industry. The industry median Days Inventory is 184.15. Historically, Grace Therapeutics' own Days Inventory has ranged from 798.44 to 798.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Grace Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score
Get the complete analysis for GRCE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
